<div id="readability-page-1"><div> Hims &amp; Hers Health (NYSE: HIMS) is trying to turn GLP-1 demand, subscriber growth, and international expansion into a much larger healthcare platform. The stock has dropped sharply, margins are under pressure, and valuation still looks demanding, but the long-term upside could become more compelling if Hims proves it can cross-sell into higher-margin care categories.Stock prices used were the market prices of May 28, 2026. The video was published on June 4, 2026.Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an &#34;Indispensable Monopoly&#34; providing the critical technology Nvidia and Intel both need. Continue »<h2>Should you buy stock in Hims &amp; Hers Health right now?</h2> Before you buy stock in Hims &amp; Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims &amp; Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,847!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,342,065!* Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 211% for the S&amp;P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of June 5, 2026. Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims &amp; Hers Health. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

HIMS

HIMZ

HIMY

Hims & Hers Health (NYSE: HIMS) is expanding its healthcare platform via GLP-1 demand and international growth, despite recent stock drops and margin pressures. While long-term upside exists if cross-selling succeeds, Motley Fool's Stock Advisor did not include HIMS in its current top 10 buy recommendations, favoring other stocks with higher potential returns.

Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock